Do different brands of oral contraceptives differ in their effects on cardiovascular disease?

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 104, Issue 5, 1997, Pages 516-520

  Crook, David ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DESOGESTREL; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; GESTAGEN; GESTODENE; HIGH DENSITY LIPOPROTEIN; LEVONORGESTREL; MESTRANOL; NORETHISTERONE; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT;

ACNE; CARDIOVASCULAR DISEASE; DRUG MIXTURE; DRUG SAFETY; EUROPEAN UNION; FEMALE; HEART INFARCTION; HIRSUTISM; HUMAN; NOTE; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STROKE; THROMBOEMBOLISM; UNITED KINGDOM;

CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE--PHARMACODYNAMICS; CONTRACEPTIVE AGENTS, PROGESTIN--PHARMACODYNAMICS; CONTRACEPTIVE AGENTS--PHARMACODYNAMICS; CONTRACEPTIVE METHODS--SIDE EFFECTS; CRITIQUE; DESOGESTREL--PHARMACODYNAMICS; DEVELOPED COUNTRIES; DISEASES; EMBOLISM; EUROPE; EVALUATION; FAMILY PLANNING; GESTODENE--PHARMACODYNAMICS; NORTHERN EUROPE; ORAL CONTRACEPTIVES, COMBINED--SIDE EFFECTS; ORAL CONTRACEPTIVES--SIDE EFFECTS; RISK ASSESSMENT; THROMBOEMBOLISM; UNITED KINGDOM; VASCULAR DISEASES;

CARDIOVASCULAR DISEASES; CONSUMER PRODUCT SAFETY; CONTRACEPTIVES, ORAL; EUROPEAN UNION; FEMALE; GREAT BRITAIN; HUMANS; PROGESTERONE CONGENERS;

EID: 0030910642     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.1997.tb11524.x     Document Type: Note

References (23)

1. Vessey MP. The Jephcott Lecture, 1989. An overview of the benefits and risks of combined oral contraceptives. In: Mann RD, editor. Oral Contraceptives and Breast Cancer: The Implications of the Present Findings for Informed Consent and Informed Choice. New Jersey, USA: The Parthenon Publishing Group, 1989:121–135.
2. Godsland IF, Crook D. Update on the metabolic effects of steroidal contraceptives and theii relationship to cardiovascular disease risk, Am J Obstet Gynecol 1994; 170: 1528–1536.
3. Inman WHW, Vessey MP, Westerhlom B, Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs. BMJ 1970; 2:203–209.
4. Kay CR. Progestogens and arterial disease-evidence from the Royal College of General Practitioners' study. Am J Obstet Gynecol 1982; 142:762–765.
5. Godsland IF, Crook D, Wynn V. Prescribing oral contraceptives. Nature 1996; 379: 764.
6. Godsland IF, Crook D, Simpson R et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990; 323: 1375–1381.
7. Speroff, L, deCherney A, Burkman RT et al. Evaluation of a new generation of oral contraceptives. Obstet Gynecol 1993; 81: 1034–1047.
8. Fruchart JC, Ailhaud G. Apolipoprotein A-containing lipoprotein particles: physiological role, quantitation, and clinical significance. Clin Chem 1992; 38: 793–797.
9. Anonymous. Whipping up panic about the pill. Nature 1995; 337: 663.[See also response: Rawlins MD. Panic and the pill. Nature 1996; 379:202.].
10. Wynn V, Godsland IF, Crook D, Stevenson JC. Committee's action will undermine further research and development. BMJ 1995; 311: 1639–1640.
11. Guillebaud J. Advising women on which pill to take. BMJ 1995; 311: 1111–1112.
12. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346: 1575–1582.
13. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effects of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346:1582–1588.
14. Spitzer WO, Lewis MA, Heinemann LAJ et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ 1996; 312: 83–88.
15. Jick H, Jick S, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with differing progestogen components. Lancet 1995; 346:1589–1593.
16. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestogen. Lancet 1995;346:1593–1596.
17. Mills AM, Wilkinson CL, Bromham DR et al. Guidelines for pre- scribing combined oral contraceptives. BMJ 1996; 312: 121–122.
18. Vessey M, Mant D, Smith A, Yeates D. Oral contraceptives and venous thromboembolisnv. findings in a large prospective study. BMJ 1986; 292: 526.
19. Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991; 133:32–37.
20. Rekers H, Norpoth T, Michaels MA. Oral contraceptive use and venous thromboembolism: a consideration of the impact of bias and confounding factors on epidemiological studies. Ear J Contracept Reprod Health Care 1996; 1: 21–30.
21. Lewis MA, Spitzer WO, Heinemann LAJ et al. Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. BMJ 1996; 312: 88–90.
22. Prasad RN, Koh S, Ratnam SS. Effects of three types of combined OC pills on blood coagulation, fibrinolysis and platelet function. Contraception 1989; 39: 369–383.
23. Koster T, Rosendaal FR, Reitsma PH, Van der Velden PA, Briet E, Vandenbroucke JP. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms. Leiden Thrombophilia Study. Thromb Haemost 1994; 71: 719–722.